XBIT - NASDAQ
XBiotech Inc.
$2.37
-1.2%XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
At a Glance
Live SnapshotXBiotech Inc. Profit Bridge
Profitability Analysis
XBiotech Inc. Income Statement
XBIT • NASDAQ
| XBiotech Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
0.0 | 0.0 | 0.0 | 4M | 18.4M | 44M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||
(1.7M) | (0.0) | (0.0) | (651K) | (5.8M) | (34.5M) | (2.4M) | (2.4M) | (1.5M) | (698K) | (699K) | (0.0) | (0.0) | (0.0) | |
-1.7M | 0.0 | 0.0 | 3.4M | 12.6M | 9.4M | -2.4M | -2.4M | -1.5M | -698K | -699K | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||||
(54M) | (42.5M) | (37.5M) | (37.8M) | (37.7M) | (27.7M) | (31.2M) | (21M) | (34.1M) | (52.8M) | (37.5M) | (21.8M) | (9.9M) | (15.2M) | |
(8.3M) | (4.7M) | (4.7M) | (6.3M) | (9.4M) | (18.2M) | (7.1M) | (5.3M) | (7.6M) | (10.3M) | (6.2M) | (7.4M) | (2M) | (1.8M) | |
(47.4M) | (37.8M) | (32.8M) | (31.5M) | (28.3M) | (9.5M) | (24.1M) | (15.7M) | (26.4M) | (42.5M) | (31.3M) | (14.3M) | (7.9M) | (13.3M) | |
-55.7M | -42.5M | -37.5M | -34.5M | -25.1M | -18.3M | -31.2M | -21M | -34.1M | -52.8M | -37.5M | -21.8M | -9.9M | -15.2M | |
PRE-TAX INCOME | ||||||||||||||
(88K) | (807K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
5.6M | 9M | 10.4M | 3.8M | 467K | 2.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.7M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (750M) | (4K) | (0.0) | (0.0) | (21K) | (0.0) | (0.0) | (0.0) | |
10.4M | 3.9M | 13.2M | 902K | -376K | 5.4M | 749.7M | -144K | 909K | 2K | 27K | 54K | -2K | 3K | |
-45.3M | -38.6M | -24.3M | -33.6M | -25.5M | -12.8M | 718.5M | -21.1M | -33.2M | -52.8M | -37.5M | -21.7M | -9.9M | -15.2M | |
NET INCOME | ||||||||||||||
(235K) | -32K | (244K) | -688K | -8M | -1.6M | (49.8M) | -144K | (0.0) | -2K | -6K | -54K | (2K) | (0.0) | |
-45.5M | -38.5M | -24.6M | -32.9M | -17.4M | -11.2M | 668.6M | -21.1M | -33.2M | -52.8M | -37.5M | -21.7M | -9.9M | -15.2M |
SEC Filings
XBIT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 29, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | March 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 09, 2025 | December 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | October 15, 2025 | June 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 03, 2025 | October 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 02, 2025 | August 29, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 13, 2025 | June 30, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | July 07, 2025 | August 29, 2025 | 2025 |
Related Guides
Continue your XBIT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.